Diabetes technology & therapeutics最新文献

{"title":"Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.","authors":"Konstantinos Kitsios, Christina-Maria Trakatelli","doi":"10.1177/15209156261486127","DOIUrl":"https://doi.org/10.1177/15209156261486127","url":null,"abstract":"<p><p>Automated Insulin Delivery (AID) systems represent the most effective and safe treatment for the management of type 1 diabetes (T1D). Antidiabetic agents used for the treatment of type 2 diabetes, such as the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (RAs), the dual Glucose-dependent Insulinotropic Polypeptide and GLP-1 RA and the Sodium-Glucose co-Transporter 2 inhibitors are associated with clinically significant weight loss and cardioprotective effect. Given the increased prevalence of overweight, obesity, and cardiovascular risk in patients with T1D, the addition of these medications to AID treatment is of considerable clinical interest. In this review limited data from randomized controlled and observational trials show that in overweight and obese patients with T1D treated with AID, the addition of weekly semaglutide, or tirzepatide is associated with significant weight loss, reduction in total daily insulin dose and increase in Time In target Range (TIR) without increased risk for hypoglycemia and Diabetic Ketoacidosis (DKA). Similarly, adjunctive treatment with empagliflozin resulted in increased TIR without increase in hypoglycemia, reduction in insulin requirements, and increase in the mean plasma ketone value, although DKA remained rare. However, studies of longer duration with more participants are required to establish the long-term safety and efficacy of these interventions in patients with T1D treated with AID.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"15209156261486127"},"PeriodicalIF":7.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Continuous Glucose Monitoring for Older Adults with Diabetes: From Clinical Evidence to a Practical Implementation Pathway.","authors":"Tong Yang, Jinghao Cai, Jiaying Ni, Jingyi Lu, Jian Zhou","doi":"10.1177/15209156261485635","DOIUrl":"https://doi.org/10.1177/15209156261485635","url":null,"abstract":"<p><p>Older adults represent a growing proportion of people with diabetes and often experience hypoglycemia, glycemic variability (GV), multimorbidity, frailty, and treatment-related vulnerabilities that are not fully captured by glycated hemoglobin A1c (HbA1c) alone. Continuous glucose monitoring (CGM) provides time-resolved glucose profiles, trend information, alerts, and remote data sharing, making it well suited to safety-focused geriatric diabetes care.In this narrative review, we synthesize evidence on CGM features, randomized and real-world outcomes, patient and caregiver experience, barriers to sustained use, and practical implementation in older adults. Across studies, the principal benefits of CGM vary by diabetes type and treatment context. In older adults with type 1 diabetes, randomized evidence most consistently supports reduced hypoglycemia exposure and time below range, whereas in basal-insulin-treated type 2 diabetes, CGM primarily improves time in range and reduces hyperglycemia. CGM may also support individualized treatment adjustment by revealing nocturnal hypoglycemia, GV, and postprandial patterns that are missed by intermittent testing.Real-world studies associate CGM use with fewer acute diabetes events and hospitalizations in selected insulin-treated populations, but residual confounding limits causal interpretation. Implementation evidence shows that benefit depends on more than device performance. Usability, skin tolerability, education, alert burden, caregiver workflows, digital literacy, cost, and equitable access strongly influence sustained use.We propose a pragmatic geriatric CGM pathway with an explicit triage algorithm that emphasizes risk-based candidate selection, functional assessment, tailored device and support models, individualized alerts and glycemic goals, focused review of CGM metrics, structured education, and early follow-up. Current evidence supports CGM primarily as a safety and decision-support technology for selected older adults, particularly those using insulin or at elevated hypoglycemia risk. Future studies should include frail and cognitively impaired populations and prioritize severe hypoglycemia, falls, treatment burden, caregiver burden, acute care use, quality of life, and scalable delivery models.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"15209156261485635"},"PeriodicalIF":7.4,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Dexcom G6® and FreeStyle Libre® Sensors in Standardized Hypoxia Conditions: A Randomized Controlled Trial-FOX Study.","authors":"Nathanaël Bassas Letissier, Christophe Rault, Corentin Faucher, Emilie Rabois, Lisa Durocher, Claire Bouleti, Stéphanie Ragot, Samy Hadjadj, Helena Mosbah, Xavier Piguel, Benjamin Alos, Raphaël Thuillier, Pierre-Jean Saulnier","doi":"10.1177/15209156261423954","DOIUrl":"10.1177/15209156261423954","url":null,"abstract":"<p><strong>Background: </strong>Continuous glucose monitoring (CGM) systems predominantly rely on oxygen-dependent enzymatic electrochemistry. While their accuracy is well established in normoxic conditions, little evidence exists regarding their performance during hypoxia, a situation encountered during altitude exposure, air travel, or specific medical conditions. This study assessed the accuracy of two widely used glucose-oxidase CGM systems (FreeStyle Libre® and Dexcom G6®) during controlled hypoxia.</p><p><strong>Methods: </strong>In a randomized controlled study, healthy volunteers and participants with diabetes were exposed to standardized normobaric hypoxia (fraction of inspired oxygen of 14.5%). Participants simultaneously wore FreeStyle and Dexcom sensors. Venous plasma glucose, analyzed using the hexokinase method, served as the reference. To induce glycemic excursions, participants consumed a standardized mixed meal and performed moderate-intensity cycling exercise. The primary end point was the mean absolute relative difference (MARD) comparing CGM values with reference glucose. Secondary assessments included consensus error grid analysis (CEGA).</p><p><strong>Results: </strong>Thirty participants were included (15 healthy volunteers and 15 with diabetes). Median age was 29.5 (interquartile range [IQR]: 23.0-41.0) years, and median body mass index was 23.3 (IQR, 22.0-26.4) kg/m². Among participants with diabetes, 53% had type 1 diabetes and 47% type 2, with a median diabetes duration of 16.3 [IQR, 11.3-21.6] years and HbA1c of 7.5% [IQR, 6.6-7.8]. During hypoxia MARD values were 21.2% for FreeStyle and 41.8% for Dexcom in healthy volunteers and 11.8% and 17.5%, respectively, in participants with diabetes. CEGA showed that 97% of FreeStyle and 87% of Dexcom readings fell within zones A or B during hypoxia.</p><p><strong>Conclusions: </strong>Both CGM systems showed reduced accuracy under hypoxia, particularly during dynamic glycemic changes. Awareness of these limitations and selective confirmation with capillary testing can assist safe use when clinically relevant decisions are required. The implications for automated insulin delivery systems warrant further dedicated evaluation.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"969-979"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of a Continuous Glucose Monitor in the Intensive Care Unit.","authors":"Eric Cucchi, Asem Ali, Yurima Guilarte-Walker, Bruce Barton, Samir Malkani, John Mordes","doi":"10.1177/15209156261423933","DOIUrl":"10.1177/15209156261423933","url":null,"abstract":"<p><strong>Objectives: </strong>Continuous glucose monitoring (CGM) devices are routinely used in the outpatient management of diabetes. They are not yet approved for use in intensive care units (ICUs). The main objective of this study was to determine the accuracy of CGM glucose determinations made in an ICU by comparing them with standard glucose measurements obtained during routine care. Secondary objectives were to determine the frequency of device malfunctions or adverse events and to assess acceptance of CGM use by caregivers.</p><p><strong>Methods: </strong>Dexcom™ G7 CGM sensors were placed on non-randomized, consented ICU patients with known hyperglycemia. CGM glucose concentrations were recorded in a Dexcom Clarity™ database and compared with near-simultaneous (±5 min) measurements obtained by laboratory or point-of-care measurements recorded in an electronic medical record. Determinations of accuracy were made using a Clarke Error Grid plot and by calculating mean absolute relative difference (MARD). Device failure and adverse event data were recorded in the electronic record. Caregiver acceptance was assessed by interview.</p><p><strong>Results: </strong>During a 9-month period, 16 subjects were enrolled after obtaining informed consent. The median duration of CGM use on subjects was 5.5 (range 1-20) days. A total of 941 near-simultaneous CGM and routine care data were collected. Clarke Error Grid comparison of CGM and routine care data showed 99.7% of readings in regions A or B and 0.3% in other regions. The MARD of all readings was 12.25%. There were no adverse events attributable to the CGM recorded. Qualitative analysis of nursing responses revealed no concerns regarding the addition of CGM to the routine workflow.</p><p><strong>Conclusion: </strong>CGM glucose readings in the ICU may be reliable to use in certain critically ill patient populations. CGM may not be reliable in patients requiring high-dose vasopressors. The use of CGM to enhance patient care in ICUs merits additional research.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"916-923"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Use of Automated Insulin Delivery in Young People with Type 1 Diabetes and Elevated HbA1c: 52-Week Outcomes of the CO-PILOT Trial.","authors":"Marcus C Ward, Alisa Boucsein, Yongwen Zhou, Venus R Michaels, Jillian J Haszard, Craig A Jefferies, Esko J Wiltshire, Ryan G Paul, Caleb A Lopez-Sanchez, Martin I de Bock, Benjamin J Wheeler","doi":"10.1177/15209156261426883","DOIUrl":"10.1177/15209156261426883","url":null,"abstract":"<p><strong>Aims: </strong>To assess longer term outcomes of automated insulin delivery (AID) in young people (7-25 years) with type 1 diabetes (T1D) and baseline glycated hemoglobin (HbA1c) ≥ 69 mmol/mol (8.5%).</p><p><strong>Methods: </strong>This 52-week, multicenter trial followed 74 participants through an initial 13-week randomized controlled trial comparing AID (MiniMed™ 780G [MM780G]) with standard care (multiple daily injections or continuous subcutaneous insulin infusion) and a 39-week continuation phase where all participants used AID. Due to differing AID exposure times, pooled data are presented for 39 weeks, with 52-week data reflecting extended follow-up for the \"AID first\" group. Outcomes included HbA1c, continuous glucose monitoring metrics, safety, system performance, and psychosocial measures.</p><p><strong>Results: </strong>Baseline mean (± standard deviation) HbA1c for all participants (<i>n</i> = 74) was 92 ± 20 mmol/mol (10.5 ± 1.9%). At 52 weeks, the mean HbA1c for the \"AID first\" group (<i>n</i> = 34) was 67 ± 18 mmol/mol (8.3 ± 1.6%), consistent with the 39-week value for all participants (67 ± 12 mmol/mol [8.3 ± 1.1%]). This followed an initial rapid decrease (mean change: -28 [95% confidence interval (CI): -33, -23] mmol/mol or -2.5 [95% CI: -3.0, -2.1] percentage points at 13 weeks post-AID) and stabilized from 26 weeks in the whole sample. Baseline mean time in range (TIR; 3.9-10 mmol/L) for all available participants (<i>n</i> = 68) was 23.1 ± 13.4%. Following substantial improvement and stabilization with AID use, the mean TIR for the \"AID first\" group (<i>n</i> = 32) was 63.1 ± 13.7% at 52 weeks. Compared with the 52 weeks before the trial, the diabetic ketoacidosis rate decreased substantially (mean difference: -35.7 events per 100 participant-years), and no severe hypoglycemia occurred. Improved treatment satisfaction and reduced fear of hypoglycemia were reported at 52 weeks.</p><p><strong>Conclusion: </strong>In young people with T1D and markedly elevated glycemia, longer term AID use with MM780G provided substantial, sustained improvements in glycemia without compromising safety. These findings support broader AID adoption in this high-risk population (Australian New Zealand Clinical Trials Registry number ACTRN12622001454763).</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"980-991"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Hypoglycemia Assessed by Continuous Glucose Monitoring: A Proposal to Define the End of a Hypoglycemic Event More Precisely.","authors":"Douglas B Muchmore, Peter Calhoun, Lutz Heinemann","doi":"10.1177/15209156261423957","DOIUrl":"10.1177/15209156261423957","url":null,"abstract":"","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"1001-1002"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemic Outcomes During Outpatient Use of Automated Insulin Delivery Without Meal Announcement in Adults with Type 1 Diabetes: Results from the CLOSE IT Randomized Controlled Trial.","authors":"Tom Wilkinson, Natalie Nanayakkara, David Burren, Alicia Jenkins, Jonathan Williman, Celeste Keesing, Erin Boyle, Yasser Elghattis, Alison Bennett, Tim Gunn, Martin de Bock, Neale D Cohen","doi":"10.1177/15209156261423558","DOIUrl":"10.1177/15209156261423558","url":null,"abstract":"<p><strong>Introduction: </strong>Current automated insulin delivery (AID) systems recommend manual insulin delivery prior to meals (hybrid closed-loop [HCL]). Data are needed on the efficacy of an AID system without meal announcement.</p><p><strong>Materials and methods: </strong>In this randomized, open-label, parallel-arm trial, we established participants with type 1 diabetes aged 18-70 years on an open-source AID system, with meal announcement, during a 12-week run-in phase, followed by a 12-week trial phase with assignment in a 1:1 ratio to AID without meal announcement or HCL (continued meal announcement). The primary outcome was the percentage of time in the target glucose range of 70-180 mg/dL (3.9-10.0 mmol/L) in the final 14 days of the trial phase, adjusted for the same metric in the final 14 days of the run-in phase.</p><p><strong>Results: </strong>In total, 73 participants underwent randomization (36 to AID without meal announcement and 37 to HCL). Mean (±standard deviation) time in the target range at the end of the run-in and trial phases was 69 ± 11% and 66 ± 8% in the AID without meal announcement and 70 ± 9% and 69 ± 13% in the HCL group (adjusted difference, -2.2 percentage points; 95% confidence interval: -6.2 to 1.7).</p><p><strong>Conclusions: </strong>In adults with type 1 diabetes, use of an open-source AID system without meal announcement demonstrated glycemic efficacy and achieved a similar time in the target glucose range to use of the same system as HCL.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"941-950"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Real-Time Continuous Glucose Monitoring System in Hospitalized Patients with Diabetes and Chronic Kidney Disease.","authors":"Yoshinori Kakutani, Tomoaki Morioka, Shoko Miyamoto, Yuka Natsuki, Yuya Miki, Akinobu Ochi, Masanori Emoto","doi":"10.1177/15209156261423902","DOIUrl":"10.1177/15209156261423902","url":null,"abstract":"<p><strong>Objective: </strong>Real-time continuous glucose monitoring (CGM) systems are beneficial for patients with diabetes by providing a comprehensive assessment of glycemic status and reducing hypoglycemia. However, their performance in patients with both diabetes and chronic kidney disease (CKD) during hospitalization remains unclear. This study aimed to evaluate the accuracy of real-time CGM in hospitalized patients with diabetes and CKD.</p><p><strong>Research design and methods: </strong>We conducted a prospective observational study including 52 patients with diabetes after excluding those with acute kidney injury, active glomerulonephritis, requiring intensive care, or undergoing hemodialysis. Participants were categorized by estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) into G1-2 (≥60), G3 (30-59), and G4-5 (<30). Capillary glucose values were measured with a validated point-of-care (POC) device and paired with corresponding real-time CGM (G6, Dexcom) readings. Accuracy was assessed by mean absolute relative difference (MARD), correlation analyses, Bland-Altman plots, and consensus error grid (CEG) analyses.</p><p><strong>Results: </strong>A total of 1603 paired glucose values were analyzed, including 752 in G1/2, 571 in G3, and 280 in G4/5. CGM and POC glucose were strongly correlated (<i>r</i> = 0.91, <i>P</i> < 0.001). The overall MARD was 17.0%, with group-specific values of 19.4% in G1/2, 15.5% in G3, and 13.5% in G4/5 (<i>P</i> < 0.001). Bland-Altman plots showed smaller bias and narrower limits of agreement in advanced CKD. CEG analyses demonstrated high agreement, with >99% of values within clinically acceptable zones.</p><p><strong>Conclusions: </strong>The Dexcom G6 demonstrated reliable accuracy in hospitalized patients with diabetes and CKD, with better performance in advanced CKD. These findings support its clinical utility in this population.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"958-968"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Dual Glucose-Ketone Monitoring as a Pump/AID Sick-Day Prevention Standard for Diabetic Ketoacidosis.","authors":"Dured Dardari","doi":"10.1177/15209156261423932","DOIUrl":"10.1177/15209156261423932","url":null,"abstract":"","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"999-1000"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Continuous Glucose Monitor on Health Care Resource Utilization in Adults with Type 2 Diabetes Managed by Noninsulin Therapies.","authors":"Anup K Sharma, Abraham Lee, Shivani Mehta, Qaashif Panjwani, Bhavya Sree Burugapalli","doi":"10.1177/15209156261423934","DOIUrl":"10.1177/15209156261423934","url":null,"abstract":"<p><strong>Background: </strong>Daily use of continuous glucose monitoring (CGM) has been shown to reduce diabetes-related events and associated costs in individuals with type 2 diabetes (T2D) regardless of their therapy. However, adoption of CGM among the large majority of T2D adults in the United States who are treated with noninsulin therapies has been limited.</p><p><strong>Methods: </strong>This retrospective database study assessed the effects of CGM acquisition on health care resource utilization (HCRU) in a large cohort of T2D adults treated with noninsulin, antidiabetes therapies. Inclusion criteria were T2D diagnosis, age ≥18 years, treated with noninsulin therapies, CGM-naive before CGM acquisition, and continuous medical/pharmacy insurance coverage during the 12-month preindex and postindex periods. The primary outcome measures were changes in all-cause hospitalizations (ACH), emergency department (ED) visits, acute diabetes complications, hyperglycemic events (HGE), and diabetic ketoacidosis (DKA) during the 12 months following CGM acquisition.</p><p><strong>Results: </strong>A total of 20,468 adults with T2D were included in this analysis. CGM acquisition was associated with significant reductions in event rates in the postindex period compared with the preindex period HCRU at 12 months: ACH (-25%), ED visits (-7%), HGE (-7%), DKA (-86%), and acute diabetes complications (-7%), all <i>P</i> < 0.0001. Similar reductions in events per person were also observed: ACH (-20.6%), ED visits (-7.2%), HGE (-6.2%), DKA (-63.0%), and acute diabetes complications (-6%), all <i>P</i> < 0.0001. Significant reductions were also seen in patients with cardiovascular disease. ACH and ED visits decreased by 35% and 12%, respectively; in those with liver disease by 25% and 13%; in those with renal disease, ACH decreased by 33%; and in those with hypertension, ACH and ED visits decreased by 26% and 7%, respectively. All reductions were statistically significant (<i>P</i> < 0.01).</p><p><strong>Conclusions: </strong>This analysis demonstrated an association between CGM acquisition and reductions in HCRU in adults with T2D treated with noninsulin therapies.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"951-957"},"PeriodicalIF":7.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}